12-Month Lobbying Summary - In-house Corporation

• Subject matter details in previous versions

  Details Regarding the Identified Subject Matter

  Subject matters	Details	Categories
  Subject matters were not required to be associated with subject matter details when this content was submitted	As a member company, participation in the Canadian Generic Pharmaceutical Association's legal challenge of the 2006 Amendments to Health Canada's Food and Drug Regulations with respect to the extended period of data exclusivity, as well as further proposed amendments to these regulations.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	As part of its renewed biomanufacturing strategy, the Federal Governement has announced its intentions to reinvest in this strategic sector. Sandoz Canada is interested in initiating discussions in this contexte with the potential objective of a joint investment in the life sciences sector.	Grant, Contribution or Other Financial Benefit
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada regarding Patented Medicine Prices Review Board (PMPRB) Reform and National Pharmacare Program	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada regarding regulation about Requirement for reporting of drug shortages.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada regarding the Cannabis Act (C-45) for medicinal cannabis	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada regarding the development and implementation of an approval pathway for Biosimilars as well as pricing policies.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada regarding the need for appropriate, dedicated resources for the Therapeutic Products Directorate to meet performance targets for the review of generic drug submissions.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Health Canada, Innovation, Science & Economic Development Canada and International Trade Canada regarding effective measures to combat counterfeit drugs in Canada and around the world.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Innovation, Science & Economic Development Canada regarding export provisions of the Patent Act (pharmaceuticals).	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Innovation, Science & Economic Development Canada regarding the need to restore balance to the Patented Medicines (Notice of Compliance) Regulations with respect to pharmaceuticals and address operational concerns including: lack of finality to proceedings under the Regulations and lack of disincentives to discourage abuse of the Regulations.	Regulation
  Subject matters were not required to be associated with subject matter details when this content was submitted	Innovation, Science & Economic Development, with respect to the Patent Act as it pertains to pharmaceuticals.	Legislative Proposal, Bill or Resolution
  Subject matters were not required to be associated with subject matter details when this content was submitted	Provide input into Government of Canada's Science and Technology strategy regarding the need for a balanced Intellectual Property regime and the important role competition plays in encouraging innovation.	Policies or Program
  Subject matters were not required to be associated with subject matter details when this content was submitted	Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) and re-negotiation of NAFTA with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.	Legislative Proposal, Bill or Resolution

  Subject matters in previous versions

  • Consumer Issues
  • Economic Development
  • Federal-Provincial Relations
  • Health
  • Industry
  • Intellectual Property
  • Justice and Law Enforcement
  • Science and Technology
  • Transportation

Government Institutions

• Canada Border Services Agency (CBSA)
• Canada Revenue Agency (CRA)
• Competition Tribunal (CT)
• Global Affairs Canada (GAC)
• Health Canada (HC)
• House of Commons
• Innovation, Science and Economic Development Canada (ISED)
• Justice Canada (JC)
• Patented Medicine Prices Review Board (PMPRB)
• Prime Minister's Office (PMO)
• Public Health Agency of Canada (PHAC)
• Senate of Canada
• Transport Canada (TC)
• Treasury Board Of Canada Secretariat (TBS)

Communication techniques

Communication techniques that have been used or are expected to be used in the course of the undertaking:

• Oral communication
• Written communication
• Grass-roots communication

Senior Officers whose lobbying activities represent less than 20% of their Duties

• Sonia Gallo, Vice-President, Regulatory Affairs | No public offices held
• Catherine Rousseau, Senior director, BioGx Market Access | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

• Guillaume Lefevre, Director, Government Affairs | No public offices held
• Christian Ouellet, Vice-président Affaires corporatives | No public offices held